dr. david f. mcdermott on nivolumab in rcc
Published 8 years ago • 180 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
1:22
dr. mcdermott on major findings of efficacy and safety of nivolumab in rcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
1:02
dr. mcdermott on novel immunotherapy combinations in rcc
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
12:48
myopericytoma...inside a big blood vessel! (intravascular myopericytoma)
-
2:16
what is nivolumab (optivo)? [vlog 21]
-
8:46
today immunotherapy can cure even fourth stage cancer: dr dattatreyudu nori
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
2:18
dr. mcdermott on immunotherapy-related aes in rcc
-
1:15
dr. mcdermott on single-agent versus combination immunotherapy in rcc
-
4:05
long-term rcc data with nivolumab
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
1:58
dr. mcdermott on single-agent pembrolizumab in advanced rcc
-
6:02
second and third-line decisions in rcc
-
1:24
dr. mcdermott on the use of anti–pd-1 combinations in mrcc
-
7:50
a look to the future in rcc
-
1:51
dr. mcdermott on vegf plus pd-1 in renal cell carcinoma
-
1:25
dr. mcdermott discusses pd-l1 expression in kidney cancer